EUVIMEDEUVIMED entdecken
Scoping ReviewOpen Access · CC BY 4.0

Late Complications After European Medicines Agency-Approved Chimeric Antigen Receptor T-Cell Therapy in Hematological Malignancies: A Scoping Review

Michael Eisenmann iD, Zhounan Zhu, Volker Arndt iD, Melissa S Y Thong iD

Current Oncology · 01.08.2026 · 33 (8) · 461

DOI: 10.3390/curroncol33080461 ↗

Kurz gefasst

Scoping Review in der Zeitschrift Current Oncology, online erschienen am 01.08.2026. Verfasst von Michael Eisenmann und 3 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Survivorship Outcomes and Epidemiology (C071), German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany. Hauptthemen laut MEDLINE: Hematologic Neoplasms, Immunotherapy, Adoptive, Receptors, Chimeric Antigen. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: China Scholarship Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor T-cell (CAR-T) therapy has substantially improved outcomes for patients with B-cell-associated hematological malignancies. While acute and early toxicities are well characterized, late complications (LCs) remain poorly understood. This scoping review aimed to identify and map the existing evidence on LCs in adult patients with hematological malignancies treated with CAR-T products approved by the European Medicines Agency (EMA). PubMed, Web of Science, and the Cochrane Library were searched for primary studies published from 2018 onwards. We included studies of adult patients receiving EMA-approved CAR-T therapies targeting CD19 or CD269. LCs were defined as diagnosis-based adverse events occurring ≥12 months after CAR-T infusion. Of 7715 records identified, 261 studies underwent full-text screening and 18 met the inclusion criteria. LCs clustered mainly as infections and secondary malignancies (SMs). Non-relapse mortality was reported in seven studies, with infections and SMs frequently reported as causes when cause-of-death data were available. Future studies should place emphasis on long-term clinical events after CAR-T therapy to improve the management of LCs and ultimately support better long-term outcomes for patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematologic NeoplasmsImmunotherapy, AdoptiveReceptors, Chimeric AntigenHumansEurope

Stichwörter der Autor:innen

chimeric antigen receptor T-cellhematological malignancieslate complicationsnon-relapse mortality

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Cancer Survivorship Outcomes and Epidemiology (C071), German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.
  • Medical Faculty, University of Heidelberg, 69120 Heidelberg, Germany.

ORCID-Profile: Michael Eisenmann, Volker Arndt, Melissa S Y Thong

Förderung

  • China Scholarship Council

Zitieren

APA

Eisenmann, M., Zhu, Z., Arndt, V., & Thong, M. S. Y. (2026). Late Complications After European Medicines Agency-Approved Chimeric Antigen Receptor T-Cell Therapy in Hematological Malignancies: A Scoping Review. Current Oncology, 33(8), 461. https://doi.org/10.3390/curroncol33080461

Vancouver

Eisenmann M, Zhu Z, Arndt V, Thong MSY. Late Complications After European Medicines Agency-Approved Chimeric Antigen Receptor T-Cell Therapy in Hematological Malignancies: A Scoping Review. Current Oncology. 2026;33(8):461. doi:10.3390/curroncol33080461

BibTeX
@article{Eisenmann2026,
  author = {Eisenmann, Michael and Zhu, Zhounan and Arndt, Volker and Thong, Melissa S Y},
  title = {Late Complications After European Medicines Agency-Approved Chimeric Antigen Receptor T-Cell Therapy in Hematological Malignancies: A Scoping Review},
  journal = {Current Oncology},
  year = {2026},
  volume = {33},
  number = {8},
  pages = {461},
  doi = {10.3390/curroncol33080461}
}
Kostenlos starten →